Documentation of Olanzapine (Zyprexa) in Hospice Care
Yes, it is entirely appropriate to document "hospice status and comfort measures" as the nursing rationale for olanzapine 2.5 mg BID in this patient. Olanzapine is a well-established medication in palliative and hospice care for multiple symptom management indications that directly support comfort-focused goals.
Legitimate Clinical Indications in Hospice
Olanzapine has multiple evidence-based roles in hospice and palliative care that align with comfort measures:
Primary Symptom Management Uses
Delirium Management: Olanzapine 2.5-5 mg is specifically recommended by ESMO guidelines for delirium symptom management in palliative patients, with the dose range of 2.5-5 mg daily (usually at bedtime) or as needed 1. The 2.5 mg BID dosing falls within this therapeutic range and is appropriate for managing distressing delirium symptoms that compromise patient comfort.
Nausea and Vomiting: Research demonstrates that olanzapine significantly reduces antiemetic medication requirements in palliative care patients (median doses decreased from 1.6 to 0.6 per day, P=0.0006), improves appetite, and is well-tolerated 2. Multiple studies confirm its efficacy as an antiemetic in palliative settings 3, 4.
Anxiety and Agitation: The anxiolytic properties of olanzapine make it valuable for managing distressing anxiety in hospice patients 4, 5. This directly supports comfort measures by reducing psychological distress.
Appetite Stimulation: Olanzapine increases appetite and can benefit patients with anorexia and weight loss, which may improve quality of life even in terminal stages 4.
Appropriate Documentation Language
Your nursing documentation should specify the symptom(s) being targeted, such as:
- "Olanzapine 2.5 mg BID for management of terminal delirium as part of hospice comfort care"
- "Olanzapine 2.5 mg BID for refractory nausea/anxiety in hospice patient receiving comfort measures"
- "Olanzapine 2.5 mg BID for symptom management (delirium/agitation/nausea) consistent with hospice goals of care"
Key Documentation Points
The rationale should connect the medication to specific comfort-focused outcomes:
- Reducing distressing symptoms (hallucinations, agitation, nausea)
- Improving quality of remaining life
- Supporting patient and family comfort
- Aligning with goals of care established in hospice enrollment
Avoid vague documentation. Rather than simply stating "hospice and comfort measures," specify which distressing symptom(s) the medication addresses. This demonstrates clinical reasoning and appropriate prescribing within the hospice philosophy.
Important Caveats
Monitor for adverse effects even in hospice: The 2.5 mg BID dose is conservative and appropriate, but watch for drowsiness, orthostatic hypotension, and oversedation—particularly if combined with benzodiazepines, which carries risk of respiratory depression 1. QTc prolongation occurred in 19% of palliative patients in one study 2.
The dose is evidence-based: The 2.5 mg starting dose with BID scheduling aligns with guideline recommendations for older or frail patients 1. The FDA label confirms 2.5-5 mg as appropriate starting doses with dose reductions recommended in elderly patients 6.
Recent mortality data: A 2025 study found antipsychotic initiation in hospice patients with dementia was associated with increased 180-day mortality (HR 1.16) 7. However, this must be balanced against the goal of symptom relief in hospice, where comfort supersedes longevity. Document that symptom burden justifies the medication despite potential risks.
Prescribing patterns vary widely: Hospice agency prescribing culture is the strongest predictor of whether patients receive antipsychotics—exceeding all patient-level factors 8. This underscores the importance of individualized clinical justification in your documentation rather than reflexive prescribing.